Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 16/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041646 | 0.83 | MAPK1 (0.47) | C5AR1 | |
| SCHEMBL13041624 | 0.74 | C5AR1 (0.47) | C5AR1 | |
| SCHEMBL13041636 | 0.69 | C5AR1 (0.45) | C5AR1 | |
| SCHEMBL2878324 | 0.69 | HTR2C (0.41) | P2RX7HTR2AHTR2CHTR2B | |
| SCHEMBL27782006 | 0.65 | SCN9A (0.46) | C5AR1P2RX7HTR2AHTR2CHTR2B | |
| SCHEMBL75469 | 0.62 | HTR2A (0.39) | C5AR1NOTUMHTR2AHTR2CHTR2B | |
| SCHEMBL13041632 | 0.62 | IDH1 (0.37) | C5AR1HTR2AHTR2CHTR2B | |
| SCHEMBL13041627 | 0.62 | ALDH1A1 (0.42) | — | |
| SCHEMBL20119408 | 0.62 | ACACB (0.40) | NOTUMP2RX7HTR2B | |
| SCHEMBL19910559 | 0.61 | SMN1; SMN2 (0.39) | NOTUMP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | C5AR1 265/4885NOTUM 4113/4885CACNA1S 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.